Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban
Multiple data presentations for ELIQUIS® (apixaban), an oral direct Factor Xa inhibitor being developed by Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), will be given at the European Society of Cardiology Congress, August 27-31, 2011, in Paris, France. Globally-conducted registrational studies evaluating ELIQUIS for the prevention of stroke in patients with atrial fibrillation will be presented during the congress. Of note is the first presentation of the comprehensive analysis of ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) during the Hot Line session on Sunday, August 28th. 
Pfizer Inc. announced that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase. 
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen's GlymaxX® technology. Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies. The GlymaxX® technology for production of afucosylated proteins is universally applicable, simple and potent. As a unique feature, differentiating it from other approaches, the GlymaxX® technology can also be applied to already existing antibody producer cell lines without altering their productivity. The technology can easily be integrated into Boehringer Ingelheim's high expression CHO-based BI-HEX® system. 
Nycomed today announced results for the second quarter of 2011, achieving double digit growth across emerging markets. Good progress was made in Key Products, particularly in the respiratory area. Following U.S. approval of Daliresp(TM) for the treatment of COPD earlier this year, Nycomed's partner Forest Laboratories introduced the product to the market and is preparing a full launch in the third quarter. In May, Nycomed agreed to be acquired by Takeda, subject to antitrust clearance, creating a truly global pharmaceutical business equipped to meet the needs of patients, doctors and healthcare providers. 
GlaxoSmithKline (GSK) and Enigma Diagnostics Limited have signed agreements for the supply and commercialisation on an exclusive basis of the Enigma® ML system in Europe and other designated key countries, including India, Brazil and Russia. The agreements include development by Enigma of an initial range of respiratory tests for use on its real-time Polymerase Chain Reaction (PCR) technology platform, and provide GSK the opportunity to generate revenues from further test developments in infectious diseases and in other therapeutic areas relevant to its healthcare business. 
Data published in the New England Journal of Medicine demonstrate that Bayer's once-daily, oral, direct Factor Xa inhibitor rivaroxaban (Xarelto®) successfully met the primary efficacy outcome while maintaining comparable overall bleeding rates versus warfarin in the ROCKET AF study. ROCKET AF was a double-blind global Phase III study of rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation (AF) for whom guidelines recommended oral anticoagulation.